Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Part of Lymphoma

Subtypes of Non-Hodgkin's Lymphoma

Diffuse Large B-Cell Lymphoma 22 Follicular Lymphoma 6 Mantle Cell Lymphoma 2 Mycosis fungoides 2 Burkitt's lymphoma 1 Peripheral T-cell lymphoma 1 B-cell lymphomas 0

40 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Non-Hodgkin's Lymphoma

461 trials tracked for Non-Hodgkin's Lymphoma: 42 in phase 3 or 4 and 20 with published results. The most-cited published study has 737 citations.

461Trials tracked
42Phase 3 & 4
0Recruiting
20With published results
Phase distribution
Phase 4 6 Phase 3 36 Phase 2 327 Phase 1 71 Other / NA 21
  1. Phase 3 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Completed · 737 cited
  2. Phase 3 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) Completed · 593 cited
  3. Phase 3 A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Completed · 553 cited
  4. Phase 3 Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma Completed · 536 cited
  5. Phase 3 A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN) Completed · 347 cited
  6. Phase 3 Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Completed · 176 cited
Show 44 more trials
  1. Phase 3 Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma Completed · 157 cited
  2. Phase 3 PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin Completed · 126 cited
  3. Phase 3 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed · 113 cited
  4. Phase 3 Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Completed · 102 cited
  5. Phase 3 A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab Completed · 66 cited
  6. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Completed · 61 cited
  7. Phase 3 A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) Completed · 33 cited
  8. Phase 3 A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma Completed · 23 cited
  9. Phase 3 A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL Completed · 20 cited
  10. Phase 3 Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant Completed · 18 cited
  11. Phase 3 Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention Completed · 11 cited
  12. Phase 3 Double Cord Versus Haploidentical (BMT CTN 1101) Completed · 10 cited
  13. Phase 3 A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment Completed · 6 cited
  14. Phase 4 A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM) Completed · 1 cited
  15. Phase 4 Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma Completed
  16. Phase 4 Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL) Completed
  17. Phase 4 A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) Completed
  18. Phase 4 Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms Completed
  19. Phase 4 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Completed
  20. Phase 3 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed
  21. Phase 3 Zevalin-beam for Aggressive Lymphoma Completed
  22. Phase 3 A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy Completed
  23. Phase 3 Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A Completed
  24. Phase 3 A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma Completed
  25. Phase 3 A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE) Completed
  26. Phase 3 Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells Completed
  27. Phase 3 Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss Completed
  28. Phase 3 Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma Completed
  29. Phase 3 Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia Completed
  30. Phase 3 Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma Completed
  31. Phase 3 A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL) Completed
  32. Phase 3 Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study Completed
  33. Phase 3 Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Completed
  34. Phase 3 A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma Completed
  35. Phase 3 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed
  36. Phase 3 Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) Completed
  37. Phase 2 T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts Completed
  38. Phase 2 Autologous and Allogeneic Transplant for Relapsed Lymphoma Completed
  39. Phase 2 Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant Completed
  40. Phase 2 ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Completed
  41. Phase 2 Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma Completed
  42. Phase 2 Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Completed
  43. Phase 2 Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed
  44. Phase 2 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Completed

Showing the 50 most-cited and recently-updated of 461 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Non-Hodgkin's Lymphoma: what the trials found

Several agents have been evaluated for the treatment of Non-Hodgkin's Lymphoma with established clinical data. Brentuximab vedotin demonstrated a significantly higher Objective Response Rate lasting at least 4 months (54.7% vs. 12.5%, p<0.001), higher Complete Response rates (17.2% vs. 1.6%, p=0.0002), and improved Progression-Free Survival (16.7% vs. 3.5%, p<0.001) 16.

Ibrutinib showed significant improvements in Progression-Free Survival at both 30 months (78.5% vs. 31.1%, p<0.0001) and 48 months (74.0% vs. 22.0%, p<0.0001), including a notable benefit in high-risk sub-populations 17. Additionally, Ibrutinib was associated with treatment-emergent adverse events in clinical trials 9.

Obinutuzumab showed significant improvements in Progression-Free Survival as assessed by both Independent Review Committee (14.1% vs. 29.2%, p<0.0001) and Investigator assessment (14.1% vs. 25.8%, p<0.0001), while the Objective Response Rate remained comparable between groups 19.

Other established findings include a significant improvement in Overall Response Rate with Alisertib (33% vs. 45%, p=0.038) despite non-significant differences in Progression-Free Survival and Overall Survival 21. Rituximab was evaluated for safety and efficacy, showing an overall adverse event rate of 67.4% 13, while autologous transplantation using rituxan/BEAM showed consistent platelet recovery rates across study arms 20.

Supportive care measures include G-CSF, which demonstrated high success rates in achieving specific CD34+ cell counts during apheresis 14. Temsirolimus was evaluated regarding infection and bleeding-related adverse events 12, and enzastaurin showed no significant difference in disease-free or event-free survival at 2 years 22.

Recent results — preliminary, needs further review

  • Cyclophosphamide was studied for the requirement of immunosuppression at 2 years post-transplant 1.
  • Cyclosporine was evaluated regarding the median time to onset of Grade II-IV aGVHD by day 100 2.
  • Lenalidomide showed high progression-free survival rates at 18 weeks (up to 100%) and favorable response durations at 2 years 5.
  • The AH-HA Tool in the EPIC EHR significantly increased the proportion of patients reporting discussions of non-ideal or missing CVH topics compared to standard practice 6.
  • Other recent trials included evaluations of Mosunetuzumab 3, Fludarabine 4, Cholecalciferol 7, and a non-interventional study 8.

For the clinician treating this condition

  • Brentuximab vedotin is associated with significantly higher response rates and progression-free survival compared to the control arm.
  • Ibrutinib provides a statistically significant improvement in progression-free survival, particularly notable in high-risk sub-populations (del17p/TP53 mutation/Del 11q).
  • Obinutuzumab shows significant improvements in progression-free survival while maintaining comparable objective response rates.
  • G-CSF is effective for achieving target CD34+ cell counts during apheresis.

AI synthesis of 18 cited trials, updated Aug 12, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review finds highest glyphosate exposure associated with increased NHL risk
Oncology Sys. Review
Systematic review finds highest glyphosate exposure associated with increased NHL risk Higher glyphosate herbicide exposure linked to increased lymphoma risk in research review
A systematic review and meta-analysis of 20 observational study populations found that ever exposure to glyphosate-based herbicides was not …
People with the highest glyphosate herbicide exposure had about a 38% higher chance of developing non-Hodgkin's lymphoma compared to those w…
medRxiv Apr 4, 2026
R-CVP after radiotherapy improves progression-free survival in early-stage follicular lymphoma
Hematology RCT
R-CVP after radiotherapy improves progression-free survival in early-stage follicular lymphoma Can adding a drug cocktail to radiation help keep early lymphoma from returning?
In a multicenter RCT with 150 patients with early-stage follicular lymphoma and 11.3-year median follow-up, involved-field radiotherapy plus…
Adding R-CVP drugs to radiation therapy helps early-stage lymphoma patients stay cancer-free longer, with mostly temporary side effects and …
Apr 2, 2026
Case report describes treatment response in rare dual-lesion DLBCL with heterogeneous subtypes
Oncology Sys. Review
Case report describes treatment response in rare dual-lesion DLBCL with heterogeneous subtypes Doctors describe treatment response in rare case of dual-lesion lymphoma
A case report and systematic review describes a 65-year-old female with rare dual-lesion DLBCL featuring both GCB and ABC subtypes.
Doctors treated a woman with two different rare lymphoma types in her brain and muscle, achieving stability after adjusting her chemotherapy…
Frontiers Apr 2, 2026
Case report describes management of Burkitt's lymphoma with concurrent HIV, CMV encephalitis, and salmonella bacteremia
Hematology
Case report describes management of Burkitt's lymphoma with concurrent HIV, CMV encephalitis, and salmonella bacteremia Case report describes complex treatment for man with lymphoma, HIV, and infections
A case report describes a 50-year-old man with newly diagnosed HIV, stage IV Burkitt's lymphoma with CNS and marrow involvement, CMV viremia…
Doctors managed a 50-year-old man with newly diagnosed HIV, aggressive lymphoma, and multiple serious infections through coordinated care fr…
Frontiers Mar 31, 2026

Research across Lymphoma

Related studies from across the Lymphoma family.

EBV prevalence varies widely across lymphoma subtypes, highest in ENKTL at 92.4%
Hematology Meta-analysis
EBV prevalence varies widely across lymphoma subtypes, highest in ENKTL at 92.4% EBV Presence Linked to Lymphoma Cases in People with HIV
This meta-analysis of 307 studies and over 21,140 lymphoma cases quantifies Epstein-Barr virus (EBV) prevalence across lymphoma subtypes, st…
A large review of over 21,000 cases shows that the Epstein-Barr virus is more common in certain lymphoma types among people living with HIV.
Aug 15, 2026
CircRNAs act as signaling hubs for immune checkpoints and indicators of ICI response in lymphoma
Genetics & Precision Medicine Sys. Review
CircRNAs act as signaling hubs for immune checkpoints and indicators of ICI response in lymphoma CircRNAs May Help Predict Response to Lymphoma Immunotherapy
This systematic review examines the role of circRNAs, including EBV-encoded types, in immune evasion within lymphomas. The authors conclude …
New research suggests that specific molecules called circRNAs could help doctors predict how patients with lymphoma will respond to immune c…
Frontiers Aug 7, 2026
Novel agent-based regimens provide superior efficacy and lower toxicity than traditional chemotherapy in older adults
Oncology Meta-analysis
Novel agent-based regimens provide superior efficacy and lower toxicity than traditional chemotherapy in older adults New Treatments Show Better Results for Older Adults with Hodgkin Lymphoma
This meta-analysis of 568 patients with classic Hodgkin lymphoma found that novel agent-based regimens, including Brentuximab Vedotin and PD…
Newer treatments like Brentuximab Vedotin and nivolumab show better results and fewer side effects than traditional chemotherapy for older a…
Jul 3, 2026
EBUS-TBNB yields higher diagnostic rates for lymphoma and sarcoidosis compared to EBUS-TBNA
Radiology & Imaging Meta-analysis
EBUS-TBNB yields higher diagnostic rates for lymphoma and sarcoidosis compared to EBUS-TBNA Core Biopsy Shows Higher Yield for Lymphoma and Sarcoidosis
This meta-analysis of 1434 patients with mediastinal disorders found that EBUS-TBNB provides a significantly higher diagnostic yield for lym…
A core biopsy technique may provide more accurate results than standard needle aspiration for certain conditions like lymphoma and sarcoidos…
Jun 13, 2026
Hodgkin lymphoma survival exceeds 90% in early-stage patients with modern therapy
Oncology Sys. Review
Hodgkin lymphoma survival exceeds 90% in early-stage patients with modern therapy New treatments push Hodgkin lymphoma survival above 90%
This systematic review synthesizes outcomes in Hodgkin lymphoma, reporting 5-year survival exceeding 90% in early-stage patients and long-te…
For early-stage Hodgkin lymphoma, 5-year survival now exceeds 90%. Advanced disease remission tops 75%. But long-term toxicities remain a co…
Frontiers Jun 4, 2026
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies
Hematology Sys. Review
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies Idiotype-directed CAAR-T therapy remains a hypothesis for B-cell malignancies
This narrative review discusses idiotype-directed CAAR-T therapy for B-cell malignancies including chronic lymphocytic leukemia and indolent…
A narrative review suggests idiotype-directed CAAR-T therapy is a theoretical option for B-cell cancers, not a current treatment.
Frontiers May 23, 2026
Systematic review of preclinical CBD effects in canine cancers
Cardiology Meta-analysis
Systematic review of preclinical CBD effects in canine cancers Lab tests suggest CBD may help treat cancer in dogs
This is a systematic review of preclinical studies on cannabidiol for canine cancers. It synthesizes evidence of antiproliferative and proap…
Lab tests suggest CBD may help treat cancer in dogs by slowing growth and triggering cell death, though human use remains unproven.
Frontiers May 22, 2026
Systematic review and meta-analysis links benzene exposure to increased lymphoid neoplasm risk
Oncology Meta-analysis
Systematic review and meta-analysis links benzene exposure to increased lymphoid neoplasm risk Benzene exposure linked to higher lymphoid neoplasm risk in large review
This systematic review and meta-analysis evaluated 95 human studies on benzene exposure across occupational and environmental settings. The …
A review of 95 studies shows benzene exposure is associated with a significantly higher risk of lymphoid neoplasms, including Hodgkin lympho…
May 22, 2026
Network meta-analysis compares EBUS techniques for mediastinal lymphadenopathy diagnostic yield
Oncology Meta-analysis
Network meta-analysis compares EBUS techniques for mediastinal lymphadenopathy diagnostic yield Doctors find a better way to sample swollen lymph nodes safely
This systematic review and network meta-analysis evaluated diagnostic yield across EBUS techniques in 2357 patients with mediastinal and/or …
A new freezing biopsy technique finds the cause of swollen chest nodes more often than standard needles while staying safe for patients.
Apr 28, 2026
Narrative review on gamma delta T cell therapies for hematologic malignancies and immune cytopenias
Allergy & Immunology Sys. Review
Narrative review on gamma delta T cell therapies for hematologic malignancies and immune cytopenias New T-Cells Fight Blood Cancer Without Matching Your DNA
This narrative review synthesizes evidence on gamma delta T cell therapies for acute leukemias, lymphomas, multiple myeloma, and immune cyto…
A new type of immune cell could finally treat blood cancers that other therapies cannot touch.
Frontiers Apr 24, 2026
Narrative Review Discusses Combined BTK and Bcl-2 Inhibitors With CAR-T Cell Therapy for Lymphoma
Drug Pipeline Sys. Review
Narrative Review Discusses Combined BTK and Bcl-2 Inhibitors With CAR-T Cell Therapy for Lymphoma Can combining targeted drugs with CAR-T therapy help lymphoma patients who have run out of options?
This narrative review evaluates the potential of combining small molecule targeted drugs, specifically BTK and Bcl-2 inhibitors, with CAR-T …
Combining targeted drugs with CAR-T therapy may help lymphoma patients who have run out of options by improving treatment effectiveness and …
Frontiers Apr 18, 2026
Circulating protein signature predicts severe immune-related adverse events in relapsed/refractory lymphoma
Oncology Cohort
Circulating protein signature predicts severe immune-related adverse events in relapsed/refractory lymphoma Blood protein test may help predict severe side effects in lymphoma patients
A cohort study of 98 relapsed/refractory lymphoma patients at MD Anderson and Moffitt Cancer Centers found that a circulating protein signat…
A new blood test can spot lymphoma patients at high risk for severe immune reactions before dangerous side effects start.
medRxiv Apr 14, 2026

Questions about Non-Hodgkin's Lymphoma

What is the focus of current clinical trials for Non-Hodgkin's Lymphoma?

Current clinical trials for non-Hodgkin's lymphoma (NHL) focus heavily on early-phase development of CAR-T cell therapies and the evaluation of bispecific antibodies.

Full answer →